Global Type 2 Diabetes Market 2021-2025
SKU ID : TNV-18569624 | Publishing Date : 24-May-2021 | No. of pages : 120
Detailed TOC of Global Type 2 Diabetes Market 2021-2025
• Executive Summaryo Market Overview
• Market Landscape
o Market ecosystem
o Value chain analysis
• Market Sizing
o Market definition
o Market segment analysis
o Market size 2020
o Market outlook: Forecast for 2020 - 2025
• Five Forces Analysis
o Five forces summary
o Bargaining power of buyers
o Bargaining power of suppliers
o Threat of new entrants
o Threat of substitutes
o Threat of rivalry
o Market condition
• Market Segmentation by Drug Class
o Market segments
o Comparison by Drug Class
o Insulin - Market size and forecast 2020-2025
o DPP-4 inhibitors - Market size and forecast 2020-2025
o GLP-1 receptor agonists - Market size and forecast 2020-2025
o SGLT-2 inhibitors - Market size and forecast 2020-2025
o Others - Market size and forecast 2020-2025
o Market opportunity by Drug Class
• Customer landscape
• Geographic Landscape
o Geographic segmentation
o Geographic comparison
o North America - Market size and forecast 2020-2025
o Europe - Market size and forecast 2020-2025
o Asia - Market size and forecast 2020-2025
o ROW - Market size and forecast 2020-2025
o Key leading countries
o Market opportunity by geography
o Market drivers
o Market challenges
o Market trends
• Vendor Landscape
o Overview
o Landscape disruption
• Vendor Analysis
o Vendors covered
o Market positioning of vendors
o Amgen Inc.
o AstraZeneca Plc
o Boehringer Ingelheim International GmbH
o Daiichi Sankyo Co. Ltd.
o Eli Lilly and Co.
o Merck and Co. Inc.
o Novartis AG
o Novo Nordisk AS
o Sanofi SA
o Takeda Pharmaceutical Co. Ltd.
• Appendix
o Scope of the report
o Currency conversion rates for US$
o Research methodology
o List of abbreviations
Exhibits
• 1: Key Finding 1
• 2: Key Finding 2
• 3: Key Finding 3
• 4: Key Finding 5
• 5: Key Finding 6
• 6: Key Finding 7
• 7: Key Finding 8
• 8: Parent market
• 9: Market characteristics
• 10: Offerings of vendors included in the market definition
• 11: Market segments
• 12: Global - Market size and forecast 2020 - 2025 ($ billion)
• 13: Global market: Year-over-year growth 2020 - 2025 (%)
• 14: Five forces analysis 2020 & 2025
• 15: Bargaining power of buyers
• 16: Bargaining power of suppliers
• 17: Threat of new entrants
• 18: Threat of substitutes
• 19: Threat of rivalry
• 20: Market condition - Five forces 2020
• 21: Other1 - Market share 2020-2025 (%)
• 22: Comparison by Other1
• 23: Insulin - Market size and forecast 2020-2025 ($ billion)
• 24: Insulin - Year-over-year growth 2020-2025 (%)
• 25: DPP-4 inhibitors - Market size and forecast 2020-2025 ($ billion)
• 26: DPP-4 inhibitors - Year-over-year growth 2020-2025 (%)
• 27: GLP-1 receptor agonists - Market size and forecast 2020-2025 ($ billion)
• 28: GLP-1 receptor agonists - Year-over-year growth 2020-2025 (%)
• 29: SGLT-2 inhibitors - Market size and forecast 2020-2025 ($ billion)
• 30: SGLT-2 inhibitors - Year-over-year growth 2020-2025 (%)
• 31: Others - Market size and forecast 2020-2025 ($ billion)
• 32: Others - Year-over-year growth 2020-2025 (%)
• 33: Market opportunity by Other1
• 34: Customer landscape
• 35: Market share by geography 2020-2025 (%)
• 36: Geographic comparison
• 37: North America - Market size and forecast 2020-2025 ($ billion)
• 38: North America - Year-over-year growth 2020-2025 (%)
• 39: Europe - Market size and forecast 2020-2025 ($ billion)
• 40: Europe - Year-over-year growth 2020-2025 (%)
• 41: Asia - Market size and forecast 2020-2025 ($ billion)
• 42: Asia - Year-over-year growth 2020-2025 (%)
• 43: ROW - Market size and forecast 2020-2025 ($ billion)
• 44: ROW - Year-over-year growth 2020-2025 (%)
• 45: Key leading countries
• 46: Market opportunity by geography ($ billion)
• 47: Impact of drivers and challenges
• 48: Vendor landscape
• 49: Landscape disruption
• 50: Industry risks
• 51: Vendors covered
• 52: Market positioning of vendors
• 53: Amgen Inc. - Overview
• 54: Amgen Inc. - Business segments
• 55: Amgen Inc. - Key offerings
• 56: Amgen Inc. - Key customers
• 57: Amgen Inc. - Segment focus
• 58: AstraZeneca Plc - Overview
• 59: AstraZeneca Plc - Product and service
• 60: AstraZeneca Plc - Key offerings
• 61: AstraZeneca Plc - Key customers
• 62: AstraZeneca Plc - Segment focus
• 63: Boehringer Ingelheim International GmbH - Overview
• 64: Boehringer Ingelheim International GmbH - Business segments
• 65: Boehringer Ingelheim International GmbH - Key offerings
• 66: Boehringer Ingelheim International GmbH - Key customers
• 67: Boehringer Ingelheim International GmbH - Segment focus
• 68: Daiichi Sankyo Co. Ltd. - Overview
• 69: Daiichi Sankyo Co. Ltd. - Business segments
• 70: Daiichi Sankyo Co. Ltd. - Key offerings
• 71: Daiichi Sankyo Co. Ltd. - Key customers
• 72: Daiichi Sankyo Co. Ltd. - Segment focus
• 73: Eli Lilly and Co. - Overview
• 74: Eli Lilly and Co. - Business segments
• 75: Eli Lilly and Co. - Key offerings
• 76: Eli Lilly and Co. - Key customers
• 77: Eli Lilly and Co. - Segment focus
• 78: Merck and Co. Inc. - Overview
• 79: Merck and Co. Inc. - Business segments
• 80: Merck and Co. Inc. - Key offerings
• 81: Merck and Co. Inc. - Key customers
• 82: Merck and Co. Inc. - Segment focus
• 83: Novartis AG - Overview
• 84: Novartis AG - Business segments
• 85: Novartis AG - Key offerings
• 86: Novartis AG - Key customers
• 87: Novartis AG - Segment focus
• 88: Novo Nordisk AS - Overview
• 89: Novo Nordisk AS - Business segments
• 90: Novo Nordisk AS - Key offerings
• 91: Novo Nordisk AS - Key customers
• 92: Novo Nordisk AS - Segment focus
• 93: Sanofi SA - Overview
• 94: Sanofi SA - Business segments
• 95: Sanofi SA - Key offerings
• 96: Sanofi SA - Key customers
• 97: Sanofi SA - Segment focus
• 98: Takeda Pharmaceutical Co. Ltd. - Overview
• 99: Takeda Pharmaceutical Co. Ltd. - Product and service
• 100: Takeda Pharmaceutical Co. Ltd. - Key offerings
• 101: Takeda Pharmaceutical Co. Ltd. - Key customers
• 102: Takeda Pharmaceutical Co. Ltd. - Segment focus
• 103: Currency conversion rates for US$
• 104: Research Methodology
• 105: Validation techniques employed for market sizing
• 106: Information sources
• 107: List of abbreviations